Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
AMPA receptor antagonist (antiseizure medication)

Fycompa (perampanel)

An approved treatment for Focal Epilepsy.

FDA Approved (2012)by Catalyst Pharmaceuticals
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2012

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Perampanel wherever you encounter it, plus the key facts at a glance.

Generic name
Perampanel
Brand name
Fycompa
Development code
E2007
Drug class
AMPA receptor antagonist (antiseizure medication)
Manufacturer
Catalyst Pharmaceuticals
How it's taken
Taken by mouth once daily at bedtime, which helps limit daytime dizziness and drowsiness.

A once-daily seizure medication with a mechanism no other approved drug shares: it blocks the AMPA receptor, a key docking site for the brain's main excitatory chemical.

That makes it a useful option when other drugs fail, though it carries a warning about serious mood and behavior effects.

Follow Fycompa by email

We'll email you when Fycompa's FDA label changes, when the FDA acts on it, and when new trials for Focal Epilepsy open. Unsubscribe anytime.

You'll get, for Focal Epilepsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Perampanel fits

A once-daily bedtime option for focal seizures, used alone or as an add-on, with a distinct AMPA mechanism, valuable when other drugs have not worked, but it carries a boxed warning for serious behavioral and psychiatric reactions, so it is dosed carefully and monitored.

How Perampanel works

Glutamate is the brain's main 'go' signal, and it delivers that signal by landing on receptors, including one called the AMPA receptor, on the receiving nerve cell. In a seizure, this excitatory signaling runs out of control. Perampanel sits on the AMPA receptor and dials down its response to glutamate, reducing the over-excitation that spreads a seizure.

No other approved seizure drug works primarily this way, which is why perampanel can help when sodium-channel and SV2A drugs have failed. The trade-off is that broadly reducing excitatory tone can affect mood and behavior in some people[5].

Side effects and safety

What patients report

Perampanel carries a boxed warning, the FDA's strongest, for serious psychiatric and behavioral reactions, including aggression, hostility, irritability, anger, and homicidal thoughts and threats. Anxiety was also reported in the trials. These are more likely at higher doses or when the dose is raised quickly, and patients and families should watch for and report mood or behavior changes.

Like other seizure medicines, perampanel can raise the risk of suicidal thoughts or actions, so new or worse depression or thoughts of self-harm should be reported right away. The label also warns about DRESS, a serious allergic reaction that can be life-threatening and can affect the skin, blood and organs such as the liver, and about more frequent seizures if it is stopped suddenly.

More routine side effects include dizziness, sleepiness, fatigue, unsteadiness, falls, and weight gain. Taking the dose at bedtime helps manage the dizziness and drowsiness[2].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Perampanel

Taken by mouth once daily at bedtime, which helps limit daytime dizziness and drowsiness. The dose is raised slowly, by 2mg at a time and no more often than once a week (no more often than every 2 weeks for older adults and people with mild or moderate liver problems), because side effects are dose-related. Perampanel is a Schedule III controlled substance in the U.S.[2].

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Help paying for Fycompa

With private insurance, the drugmaker's copay card can lower what you pay for Fycompa. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Focal Epilepsy was not taking new applications on November 20, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Fycompa (Perampanel)
FYCOMPA Instant Savings Card Program and FYCOMPA Patient Assistance Program
  • Copay help

    Eligible commercially insured patients may pay as little as $5; program pays up to $2,500 per year.

    For: private insurance · source
  • Other support

    Cash-paying patients may get up to $60 off per prescription, up to $720 per year.

    For: no insurance · source
  • Free medicine program

    Patient assistance for uninsured US residents who meet income criteria; financial documents required. Anyone with commercial or government coverage is not eligible.

    For: no insurance · source

Good to know: US rights to FYCOMPA are now held by Catalyst Pharmaceuticals (not Eisai); program pages and forms are Catalyst's. Savings card excludes Medicare, Medicaid, Medigap, VA, DoD and TRICARE. PAP phone on the official enrollment form: 1-888-392-6674 (fax 1-844-633-8444). The form states enrollment valid through Dec 31, 2025, so the form may be out of date. Generic perampanel is available; these programs cover brand FYCOMPA. Catalyst says in its 2025 Form 10-K that it stopped actively marketing brand FYCOMPA effective Dec 31, 2025, while still selling it, so whether these programs continue is unconfirmed.

Checked on the drugmaker's official pages on October 26, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Focal Epilepsy

  • From a charity · The Assistance Fund
    Epilepsy fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 20, 2026.

Every program and charity fund for Focal Epilepsy →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

The FDA approved perampanel in October 2012 as an add-on treatment for focal (partial-onset) seizures in patients 12 and older, based on placebo-controlled trials showing significant seizure reduction. It was later approved as monotherapy for focal seizures and as add-on therapy for primary generalized tonic-clonic seizures[1]. Today the label covers focal seizures in people 4 years and older, alone or as an add-on, and add-on treatment of primary generalized tonic-clonic seizures in people 12 and older.

Development history

Perampanel was discovered and developed by the Japanese company Eisai and launched as Fycompa in 2012, notable as the first-in-class selective AMPA receptor antagonist for epilepsy. Catalyst Pharmaceuticals closed its purchase of the U.S. rights from Eisai on January 24, 2023, and still makes Fycompa available in the U.S.[3] Generic tablets followed the end of patent protection in May 2025, and a generic oral suspension arrived that December[4]. Its unique mechanism keeps it in use for treatment-resistant seizures despite the behavioral cautions[5].

Ask anything about Perampanel
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Focal Epilepsy trials

Other Focal Epilepsy treatments

Common questions about Perampanel

▸What is Perampanel (Fycompa)?

A once-daily seizure medication with a mechanism no other approved drug shares: it blocks the AMPA receptor, a key docking site for the brain's main excitatory chemical. That makes it a useful option when other drugs fail, though it carries a warning about serious mood and behavior effects.

▸How does Perampanel work?

Glutamate is the brain's main 'go' signal, and it delivers that signal by landing on receptors, including one called the AMPA receptor, on the receiving nerve cell. In a seizure, this excitatory signaling runs out of control. Perampanel sits on the AMPA receptor and dials down its response to glutamate, reducing the over-excitation that spreads a seizure.

No other approved seizure drug works primarily this way, which is why perampanel can help when sodium-channel and SV2A drugs have failed. The trade-off is that broadly reducing excitatory tone can affect mood and behavior in some people[5].

▸What are the side effects of Perampanel?

Perampanel carries a boxed warning, the FDA's strongest, for serious psychiatric and behavioral reactions, including aggression, hostility, irritability, anger, and homicidal thoughts and threats. Anxiety was also reported in the trials. These are more likely at higher doses or when the dose is raised quickly, and patients and families should watch for and report mood or behavior changes. Like other seizure medicines, perampanel can raise the risk of suicidal thoughts or actions, so new or worse depression or thoughts of self-harm should be reported right away. The label also warns about DRESS, a serious allergic reaction that can be life-threatening and can affect the skin, blood and organs such as the liver, and about more frequent seizures if it is stopped suddenly.

More routine side effects include dizziness, sleepiness, fatigue, unsteadiness, falls, and weight gain. Taking the dose at bedtime helps manage the dizziness and drowsiness[2].

▸How is Perampanel taken?

Taken by mouth once daily at bedtime, which helps limit daytime dizziness and drowsiness. The dose is raised slowly, by 2mg at a time and no more often than once a week (no more often than every 2 weeks for older adults and people with mild or moderate liver problems), because side effects are dose-related. Perampanel is a Schedule III controlled substance in the U.S.[2].

▸Is Perampanel FDA approved?

Yes, Perampanel (Fycompa) is FDA approved (2012) for the treatment of Focal Epilepsy.

▸What is perampanel (Fycompa) used for?

The FDA approved perampanel (Fycompa) in October 2012 as an add-on treatment for focal (partial-onset) seizures in patients 12 and older, based on placebo-controlled trials showing significant seizure reduction. Today the label covers focal seizures in people 4 years and older, alone or as an add-on, and add-on treatment of primary generalized tonic-clonic seizures in people 12 and older. Its unique mechanism keeps perampanel in use for treatment-resistant seizures, and generic versions are available. [1][5]

▸How does perampanel work?

Perampanel sits on the AMPA receptor, a key docking site for glutamate, the brain's main excitatory chemical, and dials down its response so the over-excitation that spreads a seizure is reduced. No other approved seizure drug works primarily this way, which is why perampanel can help when sodium-channel and SV2A drugs have failed. The trade-off is that broadly reducing excitatory tone can affect mood and behavior in some people. [5]

▸What are the side effects of perampanel?

Perampanel carries a boxed warning, the FDA's strongest, for serious psychiatric and behavioral reactions, including aggression, hostility, irritability, anger, and homicidal thoughts and threats; these are more likely at higher doses or when the dose is raised quickly. Like other seizure medicines, it can raise the risk of suicidal thoughts or actions, and the label also warns about DRESS, a serious allergic reaction, and about more frequent seizures if it is stopped suddenly. More routine side effects include dizziness, sleepiness, fatigue, unsteadiness, falls and weight gain, and taking the dose at bedtime helps manage the dizziness and drowsiness. [2]

▸How is perampanel taken?

Perampanel is taken by mouth once daily at bedtime, which helps limit daytime dizziness and drowsiness. The dose is raised slowly, by 2mg at a time and no more often than once a week (every 2 weeks for older adults and people with mild or moderate liver problems), because its side effects are dose-related. Perampanel is a Schedule III controlled substance in the U.S. [2]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Eisai Inc.. Eisai Announces FDA Approval of FYCOMPA (perampanel) for the Adjunctive Treatment of Partial-Onset Seizures. https://media-us.eisai.com/2012-10-22-Eisai-Announces-FDA-Approval-of-FYCOMPA-perampanel-for-the-Adjunctive-Treatment-of-Partial-Onset-Seizures-in-Patients-with-Epilepsy-Age-12-and-Older
  2. U.S. National Library of Medicine, DailyMed. FYCOMPA (perampanel) tablets and oral suspension, CIII: Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71cf3309-e182-473c-8b0b-280cabd0e122
  3. Catalyst Pharmaceuticals. Partner With Us: FYCOMPA. https://www.catalystpharma.com/our-collaborations
  4. Catalyst Pharmaceuticals. Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance. https://ir.catalystpharma.com/news/news-details/2026/Catalyst-Pharmaceuticals-Reports-Record-Fourth-Quarter-and-Record-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx
  5. PMC. Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy. https://pmc.ncbi.nlm.nih.gov/articles/PMC5083075/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Fycompa by email

We'll email you when Fycompa's FDA label changes, when the FDA acts on it, and when new trials for Focal Epilepsy open. Unsubscribe anytime.

You'll get, for Focal Epilepsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site